Protagenic Therapeutics, Inc. (PTIX) earnings
PTIX earnings moved a median of 0.00% by the close. Quarterly and annual PTIX reports and results, each read against the price at its own news timestamp. Back to the PTIX overview →
20 measured PTIX earnings events.
Where these PTIX earnings landedvs 19 measured PTIX earnings reactions
| Middle 50% of PTIX earnings reactions | -2.12% to +9.21% |
|---|---|
| Median reaction (to close) | 0.00% |
| Measured reactions | 19 |
Point-in-time · zero look-ahead
Half of the 19 PTIX earnings events with a measured close landed between -2.12% and +9.21%; 47% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Protagenic Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | +0.00% | +50.04% | |
| Form 10-K Protagenic Therapeutics, For: Mar 31 | SEC filing · Form 10-K | — | +0.00% | |
| Form NT 10-Q Protagenic Therapeutics, For: Jun 30 | SEC filing · Form NT | — | +0.00% | |
| Form NT 10-K Protagenic Therapeutics, For: Mar 31 | SEC filing · Form NT | — | — | |
| Form 10-Q Protagenic Therapeutics, For: Dec 31 | SEC filing · Form 10-Q | +0.00% | -6.53% | |
| Form NT 10-Q Protagenic Therapeutics, For: Dec 31 | SEC filing · Form NT | +0.00% | +20.00% | |
| Form 10-Q Protagenic Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | +4.19% | +11.52% | |
| Form NT 10-Q Protagenic Therapeutics, For: Sep 30 | SEC filing · Form NT | +0.00% | -0.48% | |
| Protagenic Therapeutics Provides Update on Form 10-Q Filing Timeline and Nasdaq Compliance | Press release | +14.52% | +11.08% | |
| Form NT 10-Q Protagenic Therapeutics, For: Jun 30 | SEC filing · Form NT | +0.00% | -6.98% | |
| Form 10-Q Protagenic Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +1.89% | +2.18% | |
| Form 10-K Protagenic Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +0.00% | -6.20% | |
| Form 10-Q Protagenic Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | +0.00% | -5.58% | |
| Form 10-Q Protagenic Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | -0.14% | +7.33% | |
| Form 10-Q Protagenic Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | — | +14.62% | |
| Form 10-K/A Protagenic Therapeutics, For: Dec 31 | SEC filing · Form 10-K | -2.73% | -2.34% | |
| Form 10-K/A Protagenic Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +0.00% | +2.38% | |
| Form 10-K Protagenic Therapeutics, For: Dec 31 | SEC filing · Form 10-K | — | -1.17% | |
| Protagenic Therapeutics Schedules First Q4 and FY 2023 Earnings Call | Press release | +2.06% | +4.79% | |
| Form 10-Q Protagenic Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | — | -1.89% |
Keep exploring
More PTIX: analyst actions → · SEC filings → · PTIX overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| ZIVO BIOSCIENCE INC (ZIVO) | 122 | 0.00% | 29% |
| American Shared Hospital Services (AMS) | 121 | 0.00% | 48% |
| Xenetic Biosciences, Inc. (XBIO) | 121 | 0.00% | 38% |
| Avenue Therapeutics, Inc. (ATXI) | 120 | 0.00% | 37% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.